Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 9Completed 8Active not recruiting 8Terminated 4Withdrawn 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Pancreatic Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Neoplasms 4Breast Neoplasms 4Lung Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Platinum-Refractory Fallopian Tube Carcinoma 2Inflammatory Breast Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma, Ovarian 1Teratoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrent Bladder Urothelial Carcinoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1

Interventions

Carboplatin 18Radiotherapy 10Cisplatin 10Pemetrexed 8Paclitaxel 8durvalumab 6Magnetic Resonance Spectroscopy 6Gemcitabine 6Radiosurgery 5Nivolumab 5Etoposide 5pembrolizumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Erlotinib Hydrochloride 4Docetaxel 4Taxes 3Standard of Care 3Specimen Handling 3Platinum 3Cetuximab 3Bronchoscopy 3Biopsy 3Bevacizumab 31,2-diaminocyclohexaneplatinum II citrate 3sapanisertib 2etoposide phosphate 2capmatinib 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Lung Neoplasms × Taxes × Clear all
NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04262869 2021-10-27

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Emory University

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00748163 2018-08-08

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡